WO2015138960A3 - Ré-ingénierie moléculaire de l'équilibre excitation-inhibition dans des circuits mémoire - Google Patents
Ré-ingénierie moléculaire de l'équilibre excitation-inhibition dans des circuits mémoire Download PDFInfo
- Publication number
- WO2015138960A3 WO2015138960A3 PCT/US2015/020540 US2015020540W WO2015138960A3 WO 2015138960 A3 WO2015138960 A3 WO 2015138960A3 US 2015020540 W US2015020540 W US 2015020540W WO 2015138960 A3 WO2015138960 A3 WO 2015138960A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ablim3
- memory
- excitation
- engineering
- molecular
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des agents de régulation de la mémoire et des méthodes qui permettent de cibler l'élément 3 de la famille des protéines LIM de liaison à l'actine (ABLIM3).
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/125,796 US10287580B2 (en) | 2014-03-14 | 2015-03-13 | Molecular re-engineering of excitation-inhibition balance in memory circuits |
US16/389,467 US20190241894A1 (en) | 2014-03-14 | 2019-04-19 | Molecular re-engineering of excitation-inhibition balance in memory circuits |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461952934P | 2014-03-14 | 2014-03-14 | |
US61/952,934 | 2014-03-14 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/125,796 A-371-Of-International US10287580B2 (en) | 2014-03-14 | 2015-03-13 | Molecular re-engineering of excitation-inhibition balance in memory circuits |
US16/389,467 Division US20190241894A1 (en) | 2014-03-14 | 2019-04-19 | Molecular re-engineering of excitation-inhibition balance in memory circuits |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015138960A2 WO2015138960A2 (fr) | 2015-09-17 |
WO2015138960A3 true WO2015138960A3 (fr) | 2015-11-19 |
Family
ID=54072601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/020540 WO2015138960A2 (fr) | 2014-03-14 | 2015-03-13 | Ré-ingénierie moléculaire de l'équilibre excitation-inhibition dans des circuits mémoire |
Country Status (2)
Country | Link |
---|---|
US (2) | US10287580B2 (fr) |
WO (1) | WO2015138960A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105861740B (zh) * | 2016-06-24 | 2019-07-05 | 河北医科大学第四医院 | Ablim3基因作为食管癌诊治标志物的用途 |
WO2023215805A1 (fr) * | 2022-05-05 | 2023-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions d'agent d'arni de protéine 3 lim se liant à l'actine (ablim3) et leurs procédés d'utilisation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110023143A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of neurodevelopmental genes in animals |
WO2013185108A1 (fr) * | 2012-06-07 | 2013-12-12 | Massachusetts Institute Of Technology | Méthodes et produits liés au cancer du poumon |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006113679A2 (fr) * | 2005-04-15 | 2006-10-26 | Board Of Regents, The University Of Texas System | Administration d'arnsi par compositions lipidiques neutres |
WO2011127222A1 (fr) * | 2010-04-06 | 2011-10-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnostic et traitement de mélanome par évaluation et modulation de nuak2 |
-
2015
- 2015-03-13 WO PCT/US2015/020540 patent/WO2015138960A2/fr active Application Filing
- 2015-03-13 US US15/125,796 patent/US10287580B2/en active Active
-
2019
- 2019-04-19 US US16/389,467 patent/US20190241894A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110023143A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Genomic editing of neurodevelopmental genes in animals |
WO2013185108A1 (fr) * | 2012-06-07 | 2013-12-12 | Massachusetts Institute Of Technology | Méthodes et produits liés au cancer du poumon |
Non-Patent Citations (6)
Title |
---|
ALLY ET AL.: "Pattern Separation and Pattern Completion in Alzheimer's Disease: Evidence of Rapid Forgetting in Amnestic Mild Cognitive Impairment.", HIPPOCAMPUS., vol. 23, no. 12, 2013, pages 1246 - 1258, XP055237424, ISSN: 1050-9631 * |
BARRIENTOS ET AL.: "Two Novel Members of the ABLIM Protein Family, ABLIM-2 and -3, Associate with STARS and Directly Bind F-actin.", J BIOL CHEM., vol. 282, no. 11, 2007, pages 8393 - 8403, XP055237422 * |
CHOW ET AL.: "Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype.", PROC NATL ACAD SCI U S A., vol. 104, no. 3, 2007, pages 823 - 828, XP002592369, ISSN: 0027-8424 * |
SAHAY ET AL.: "Pattem Separation: A Common Function for New Neurons in Hippocampus and Olfactory Bulb.", NEURON., vol. 70, no. 4, 2011, pages 582 - 588, XP028231885, ISSN: 0896-6273 * |
WEINER ET AL.: "Military risk factors for Alzheimer's disease.", ALZHEIMERS DEMENT., vol. 9, no. 4, 2013, pages 445 - 451, XP055237425, ISSN: 1552-5260 * |
YAMAMOTO ET AL.: "Therapeutic potential of inhibition of the NF-kB pathway in the treatment of inflammation and cancer.", J CLIN INVEST., vol. 107, no. 2, 2001, pages 135 - 142, XP002428353, ISSN: 0021-9738 * |
Also Published As
Publication number | Publication date |
---|---|
US20190241894A1 (en) | 2019-08-08 |
US20160376588A1 (en) | 2016-12-29 |
WO2015138960A2 (fr) | 2015-09-17 |
US10287580B2 (en) | 2019-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017040930A3 (fr) | Biomarqueurs prédictifs du syndrome de libération de cytokines | |
WO2016130704A3 (fr) | Procédés et compositions pour analyser des composants cellulaires | |
WO2015196128A3 (fr) | Molécules d'acide nucléique alternatives et leurs utilisations | |
WO2015196130A3 (fr) | Molécules d'acide nucléique alternatives et leurs utilisations | |
EA201892489A1 (ru) | Число мишеней для мультиплексной оптимизированной амплификации с несоответствиями (moma) | |
WO2015191911A3 (fr) | Microvésicules enrichies en protéines et leurs procédés de fabrication et d'utilisation | |
MY196882A (en) | Recombinant binding proteins and their use | |
WO2015089511A3 (fr) | Molécules d'acides nucléiques modifiés et leurs utilisations | |
EP3252172A3 (fr) | Hybridation rapide pour l'enrichissement de cible de séquençage de nouvelle génération | |
WO2016065349A8 (fr) | Arn non codants courts régulateurs de protéines (sprrna) et procédés d'utilisation | |
EP4219702A3 (fr) | Variants d'enzymes et polynucléotides codant pour ces variants | |
WO2015149034A3 (fr) | Fusions de gènes et variants de gènes associés au cancer | |
EP3964575A3 (fr) | Variants d'alpha-amylase et polynucléotides codant pour ces derniers | |
WO2016109799A3 (fr) | Procédé permettant d'isoler de l'arn à partir d'échantillons cliniques | |
WO2017053629A3 (fr) | Insertion de gènes régulée par la lumière à l'aide de vecteurs viraux par l'intermédiaire de l'incorporation de protéines optogénétiques et l'insertion génétique de peptides contraints de manière non conformationnelle | |
EP3643706A4 (fr) | Composé monomère d'acide nucléique modifié et analogue d'acide oligonucléique | |
EP3959342A4 (fr) | Procédés et kits pour l'enrichissement et la détection de modifications d'adn et d'arn et de motifs fonctionnels | |
WO2015138960A3 (fr) | Ré-ingénierie moléculaire de l'équilibre excitation-inhibition dans des circuits mémoire | |
WO2016154040A3 (fr) | Étiquetage biosynthétique et séparation d'arn | |
WO2015150482A8 (fr) | Produit de combinaison comprenant une structure d'acide nucléique et une molécule d'acide nucléique simple brin | |
WO2018231955A3 (fr) | Isolement d'acides nucléiques cibles | |
WO2016145362A3 (fr) | Inhibiteurs de protéine dek et procédés associés | |
EP3480309A4 (fr) | Ensemble d'amorces, trousse et procédé de détection d'au moins deux acides nucléiques cibles | |
WO2014136124A3 (fr) | Trousse d'essai de pcr en temps réel multiplexe pour la détection simultanée du virus de l'hépatite | |
WO2015170187A3 (fr) | Procédés d'enrichissement perfectionnés |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15761521 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15125796 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15761521 Country of ref document: EP Kind code of ref document: A2 |